Identification
Name Bretylium
Accession Number DB01158 (APRD00830)
Type small molecule
Description Bretylium blocks the release of noradrenaline from the peripheral sympathetic nervous system, and is used in emergency medicine, cardiology, and other specialties for the acute management of ventricular tachycardia and ventricular fibrillation. The primary mode of action for bretylium is thought to be inhibition of voltage-gated K(+) channels. Recent evidence has shown that bretylium may also inhibit the Na,K-ATPase by binding to the extracellular K-site.
Structure
Categories (*)
Molecular Weight 243.163
Groups approved
Monoisotopic Weight 242.054437196
Pharmacology
Indication For use in the prophylaxis and therapy of ventricular fibrillation. Also used in the treatment of life-threatening ventricular arrhythmias, such as ventricular tachycardia, that have failed to respond to adequate doses of a first-line antiarrhythmic agent, such as lidocaine.
Mechanism of action Bretylium inhibits norepinephrine release by depressing adrenergic nerve terminal excitability. The mechanisms of the antifibrillatory and antiarrhythmic actions of bretylium are not established. In efforts to define these mechanisms, the following electrophysiologic actions of bretylium have been demonstrated in animal experiments: increase in ventricular fibrillation threshold, increase in action potential duration and effective refractory period without changes in heart rate, little effect on the rate of rise or amplitude of the cardiac action potential (Phase 0) or in resting membrane potential (Phase 4) in normal myocardium, decrease in the disparity in action potential duration between normal and infarcted regions, and increase in impulse formation and spontaneous firing rate of pacemaker tissue as well as increase ventricular conduction velocity.
Absorption Not Available
Protein binding Not Available
Biotransformation No metabolites have been identified following administration in man and laboratory animals.
Route of elimination Not Available
Toxicity Oral, mouse: LD50 = 400 mg/kg. In the presence of life-threatening arrhythmias, underdosing with bretylium probably presents a greater risk to the patient than potential overdosage. However, one case of accidental overdose has been reported in which a rapidly injected intravenous bolus of 30 mg/kg was given instead of an intended 10 mg/kg dose during an episode of ventricular tachycardia. Marked hypertension resulted, followed by protracted refractory hypotension. The patient expired 18 hours later in asystole, complicated by renal failure and aspiration pneumonitis. Bretylium serum levels were 8000 ng/mL.
Affected organisms
  • Humans and other mammals
Interactions
Drug Interactions
Drug Mechanism of interaction
Cisapride Increased risk of cardiotoxicity and arrhythmias
Clarithromycin Increased risk of cardiotoxicity and arrhythmias
Erythromycin Increased risk of cardiotoxicity and arryhthmias
Gatifloxacin Increased risk of cardiotoxicity and arrhythmias
Grepafloxacin Increased risk of cardiotoxicity and arrhythmias
Levofloxacin Increased risk of cardiotoxicity and arrhythmias
Mesoridazine Increased risk of cardiotoxicity and arrhythmias
Moxifloxacin Increased risk of cardiotoxicity and arrhythmias
Ranolazine Possible additive effect on QT prolongation
Telithromycin Increased risk of cardiotoxicity and arrhythmias
Thioridazine Increased risk of cardiotoxicity and arrhythmias
Food Interactions Not Available
Sodium/potassium-transporting ATPase alpha-1 chain
Name Sodium/potassium-transporting ATPase alpha-1 chain
Gene Name ATP1A1
Pharmacological action yes
Actions inhibitor
References
  • Dzimiri N, Almotrefi AA: Inhibition of myocardial Na(+)-K(+)-ATPase activity by bretylium: role of potassium. Arch Int Pharmacodyn Ther. 1992 Jul-Aug;318:76-85. - Pubmed
  • Helms JB, Arnett KL, Gatto C, Milanick MA: Bretylium, an organic quaternary amine, inhibits the Na,K-ATPase by binding to the extracellular K-site. Blood Cells Mol Dis. 2004 May-Jun;32(3):394-400. - Pubmed
  • Dzimiri N, Almotrefi AA: Interaction of bretylium tosylate with guinea-pig myocardial Na(+)-K(+)-ATPase. Gen Pharmacol. 1991;22(5):935-8. - Pubmed
  • Tiku PE, Nowell PT: Selective inhibition of K(+)-stimulation of Na,K-ATPase by bretylium. Br J Pharmacol. 1991 Dec;104(4):895-900. - Pubmed
DTHybrid score 0.7588
Id Partner name Gene Name Score
566 Serotransferrin TF 0.0538
558 Solute carrier family 12 member 1 SLC12A1 0.0385
295 Carbonic anhydrase 1 CA1 0.0298
6150 Solute carrier organic anion transporter family member 4C1 SLCO4C1 0.028
357 Carbonic anhydrase 2 CA2 0.0223
610 Calcium-activated potassium channel subunit alpha 1 KCNMA1 0.0221
592 Carbonic anhydrase 4 CA4 0.0214
6139 Solute carrier organic anion transporter family member 1A2 SLCO1A2 0.0187
3932 Glutathione S-transferase A2 GSTA2 0.017
587 Serum albumin ALB 0.0164
6017 Cholesterol side-chain cleavage enzyme, mitochondrial CYP11A1 0.0156
1405 Thiopurine S-methyltransferase TPMT 0.0148
6158 Solute carrier organic anion transporter family member 1C1 SLCO1C1 0.0143
466 Solute carrier family 12 member 3 SLC12A3 0.0124
6157 Solute carrier organic anion transporter family member 1B3 SLCO1B3 0.0124
781 ATP-sensitive inward rectifier potassium channel 11 KCNJ11 0.0123
1588 Multidrug resistance protein 1 ABCB1 0.0123
3426 Glutamine synthetase glnA 0.0121
3987 Glutamine synthetase GLUL 0.0121
4205 Carbonic anhydrase 9 CA9 0.0118
3007 Carbonic anhydrase 12 CA12 0.0118
1490 Solute carrier organic anion transporter family member 1B1 SLCO1B1 0.0108
741 Potassium voltage-gated channel subfamily KQT member 1 KCNQ1 0.0103
6142 Solute carrier family 22 member 8 SLC22A8 0.0102
1729 Solute carrier family 22 member 6 SLC22A6 0.0098
6047 Calcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1A PDE1A 0.0093
5692 Calcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1B PDE1B 0.0087
392 Voltage-dependent P/Q-type calcium channel subunit alpha-1A CACNA1A 0.0087
1561 Troponin C, slow skeletal and cardiac muscles TNNC1 0.0081
4160 Voltage-dependent calcium channel subunit alpha-2/delta-2 CACNA2D2 0.008
4512 Cytochrome P450 3A4 CYP3A4 0.0076
964 Voltage-dependent T-type calcium channel subunit alpha-1H CACNA1H 0.0073
6167 Organic solute transporter subunit beta OSTB 0.0066
6166 Organic solute transporter subunit alpha OSTA 0.0066
6024 Cytochrome P450 1A1 CYP1A1 0.0065
465 Calmodulin CALM1 0.0062
6153 Solute carrier organic anion transporter family member 4A1 SLCO4A1 0.0054
1632 Solute carrier organic anion transporter family member 2B1 SLCO2B1 0.0042
776 Bile salt export pump ABCB11 0.0041
4119 Cytochrome P450 2D6 CYP2D6 0.0037